X

Trial Profile

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Adult Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iduronicrin genleukocel-T (Primary)
Indications Mucopolysaccharidosis I
Focus Adverse reactions; First in man
Sponsors Immusoft

Most Recent Events

13 Mar 2024 Planned End Date changed from 1 Oct 2024 to 1 Jun 2039.
13 Mar 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Jun 2025.
03 Jan 2024 According to an Immusoft media release, the company will present data from this study at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com